Log In
Print
BCIQ
Print
Print this Print this
 

Topical XEN402, TV-45070

  Manage Alerts
Collapse Summary General Information
Company Xenon Pharmaceuticals Inc.
DescriptionTopical formulation of sodium channel sub-type Nav1.7 blocker
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionNa channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat osteoarthitis (OA) pain; Treat pain associated with erythromelalgia; Treat post-herpetic neuralgia (PHN)
Regulatory Designation

U.S. - Orphan Drug (Treat pain associated with erythromelalgia)

Partner

Teva Pharmaceutical Industries Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today